Immunosuppressive effects of factor IX products: An in vitro study

Haemophilia

Volumn 5, Issue 6, 1999, Pages 416-425

  Grosset, A B ^a   McGregor, J R ^a   Samlowski, W E ^a   Rodgers, G M ^a,b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Haemophilia B; Immunodeficiency; Lymphocytes; Nitric oxide

Indexed keywords

BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CONCANAVALIN A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; NITRIC OXIDE; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANIMAL CELL; CELL STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; DIALYSIS; FLOW CYTOMETRY; HEMOPHILIA B; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MITOGENESIS; MONONUCLEAR CELL; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL CULTURE TECHNIQUES; CONCANAVALIN A; CYTOKINES; FACTOR IX; HUMANS; IMMUNOSUPPRESSION; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MACROPHAGES; MICE; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033458826     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00343.x     Document Type: Conference Paper

References (35)

1. Tartter PI. Blood transfusion and postoperative infections. Transfusion 1989; 29: 456-9.
2. Blumberg N, Trulzi DJ, Heal JM. Transfusion-induced immunomodulation and its clinical consequences. Transfusion Med Rev 1990; 4: 24-35.
3. Hilgartner MW. Changes in CD4 count relative to product usage: Findings from the Transfusion Safety Study. Semin Hematol 1993; 30 (Suppl. 5): 7-9.
4. Kaplan J, Sarnaik S, Gitlin J, Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 1984; 64: 308-10.
5. Aledort LM. Introduction. Replacement therapy for hemophilia: Impact on the immune system. Semin Hematol 1993; 30 (Suppl. 5): 1.
6. Madhok R. The treatment of hemophilia - A double-edged sword. Semin Hematol 1993; 30 (Suppl. 5): 2-6.
7. Beddall AC, Hill FGH, George RH, Williams MD, Al-Rubei K. Unusually high incidence of tuberculosis among boys with haemophilia during an outbreak of the disease in hospital. J Clin Pathol 1985; 38: 1163-5.
8. Cuthbert RJG, Ludlam CA, Steel CM, Beatson D, Peutherer JF. Immunological studies in HIV seronegative haemophiliacs: Relationships to blood product therapy. Br J Haematol 1992; 80: 364-9.
9. Matheson DS, Green BJ, Poon M-C et al. Natural killer cell activity from hemophiliacs exhibits differential responses to various forms of interferon. Blood 1986; 67: 164-7.
10. Seremetis SV. Very high purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: Conclusion of a prospective 3-year study. Semin Hematol 1993; 30 (Suppl. 5): 10-3.
11. Brettler DB, Levine PH. Factor concentrates for treatment of hemophilia: Which one to choose? Blood 1989; 73: 2067-73.
12. Eibl MM, Ahmad R, Wolf HM et al. A component of factor VIII preparations, which can be separated from factor VIII activity down-modulates human monocyte functions. Blood 1987; 69: 1153-60.
13. Vermot-Desroches C, Rigal D, Blourde C, Bernaud J. Immunosuppressive property of a very high purity antihaemophilic preparation: a low molecular weight component inhibits an early step of PHA induced cell activity. Br J Haematol 1992; 80: 370-7.
14. Gjerset GF, Pike MC, Mosley JW, et al. Effect of low-and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Blood 1994; 84: 1666-71.
15. Thomas DP. Clotting factor concentrates - Whither purity? Thromb Haemost 1995; 74: 1604-6.
16. Hay CRM, McEvoy P, Duggan-Keen M. Inhibition of lymphocyte IL2-receptor expression by factor VIII concentrate: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 1990; 75: 278-81.
17. Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 1989; 71: 387-91.
18. Wadhwa M, Dilger P, Tubbs J et al. Mechanisms of inhibition of T-cell IL-2 secretion by factor VIII concentrates. Br J Haematol 1992; 82: 575-83.
19. Madhok R, Smith J, Jenkins A, Lowe GDO. T-cell sensitization to factor VIII in haemophilia A? Br J Haematol 1991; 79: 235-8.
20. Madhok R, Gracie JA, Smith J, Lowe GDO, Forbes CD. Capacity to produce interleukin 2 is impaired in haemophilia in the absence and presence of HIV 1 infection. Br J Haematol 1990; 76: 70-4.
21. Lederman MM, Saunders C, Toossi Z, et al. Antihemophilic factor (factor VIII) preparations inhibit lymphocyte proliferation and production of interleukin -2. J Lab Clin Med 1986; 107: 471-8.
22. Mahir WS, Millard RE, Booth JC, Flute PT. Functional studies of cell-mediated immunity in haemophilia and other bleeding disorders. Br J Haematol 1988; 69: 367-70.
23. Roy G, Pardo A, Leyva-Cobian F. Phenotypic and functional abnormalities in monocytes from patients with haemophilia A treated with factor VIII concentrates. Acta Haematol 1988; 79: 26-32.
24. Madhok R, Gracie A, Lowe GDO, et al. Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Br Med J 1986; 293: 978-80.
25. Samlowski WE, Yim C-Y, McGregor JR. Nitric oxide exposure inhibits induction of lymphokine-activated killer (LAK) cells by inducing precursor apoptosis. Nitric Oxide 1998; 2: 45-56.
26. Bastian NR, Yim C-Y, Hibbs JB Jr, Samlowski WE. Induction of iron-derived epr signals in murine cancers by nitric oxide: Evidence for multiple intracellular targets. J Biol Chem 1994; 269: 5127-31.
27. Yim C-Y, Bastian NR, Smith JC, Hibbs JB Jr, Samlowski WE. Macrophage nitric oxide synthesis delays progression of ultraviolet light induced murine skin cancers. Cancer Res 1993; 55: 5507-11.
28. Erard F, Corthesy P, Nabholz M et al. Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J Immunol 1985; 134: 1644-52.
29. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by THI cells. J Immunol 1991; 146: 3444-51.
30. Kwak J-Y, Park S-Y, Han MK, et al. Receptor-mediated activation of murine peritoneal macrophages by antithrombin III acts as a costimulatory signal for nitric oxide synthesis. Cellular Immunol 1998; 188: 33-40.
31. Berntorp E. Impact of replacement therapy on the evolution of HIV infection in hemophiliacs. Thromb Haemost 1994; 71: 678-83.
32. Schögl D, Zimmermann K, Turecek PL, et al. Effect of high-versus intermediate-purity blood coagulation factor concentrates on HIV-1 replication. Vox Sang 1996; 70: 195-7.
33. Berntorp E. Why prescribe highly purified factor VIII and IX concentrates? Vox Sang 1996; 70: 61-8.
34. Limentani SA, Gowell KP, Deitcher SR. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B. Thromb Haemost 1995; 73: 584-91.
35. McDonald C, Jackson V, Kilpatrick DC, Yap PL, Prowse C. A diffusable factor in Scottish coagulation factor concentrates can inhibit lymphocyte transformation in vitro. Vox Sang 1985; 49: 187-194.